Fenwick Represents Formation Bio in AI Collaboration with Sanofi and OpenAI

Fenwick represented Formation Bio, an AI and tech-driven drug developer with its own pipeline of drug assets, in its collaboration with Sanofi and OpenAI to build a fine-tuned and custom AI-powered software to accelerate drug development and bring new medicines to patients more efficiently.

This first-in-class collaboration within the pharma and life sciences industries will help Formation Bio advance their vision of building a pharma company differentiated by radical efficiency throughout drug development and clinical trials. More information about the collaboration can be obtained from Sanofi's announcement. 

Fenwick has served as outside counsel to Formation Bio since 2016, led by corporate partner Michael Esquivel. The Fenwick transaction team was led by technology transactions partner Stefano Quintini and included associates Trevor Snider and Pinar Bailey.